Holen Sie sich die Stockscreener-App
45.47
1.86%
1.0408
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$44.43
Offen:
$44.43
24-Stunden-Volumen:
593.86K
Relative Volume:
0.29
Marktkapitalisierung:
$4.23B
Einnahmen:
$536.20M
Nettoeinkommen (Verlust:
$-45.64M
KGV:
-85.02
EPS:
-0.5348
Netto-Cashflow:
$-28.94M
1W Leistung:
+7.09%
1M Leistung:
+11.75%
6M Leistung:
+24.82%
1J Leistung:
+185.72%
1-Tages-Spanne:
$43.70
$45.53
1-Wochen-Bereich:
$42.06
$45.47
52-Wochen-Spanne:
$13.88
$48.61
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
45.48 | 4.13B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
437.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.64 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.31 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.04 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.58 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics (TVTX) grants director 4,000 shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) director receives stock and option awards - Stock Titan
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 stock options - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) grants director stock and options - Stock Titan
Travere Therapeutics (TVTX) investors back equity plan boost and all 2026 meeting items - Stock Titan
Travere Therapeutics Rides FILSPARI Surge After FDA Win - TipRanks
Insider Sell Alert: Timothy Coughlin Sells 3,250 Shares of Trave - GuruFocus
Travere Therapeutics (TVTX) director sells 3,250 shares in Rule 10b5-1 trade - Stock Titan
Stephens Investment Management Group LLC Acquires 121,955 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail
(TVTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Armistice Capital/Steven Boyd discloses 4,897,417 TVTX shares (5.27%) - Stock Titan
Why Travere Therapeutics Stock Is Tumbling Today - TipRanks
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics launches first FDA-approved therapy for rare kidney disease FSGS. - Pluang
UBS Group AG Has $16.15 Million Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
State of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Issues New Convertible Notes to Refinance Debt - TipRanks
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink - TradingView
[8-K] Travere Therapeutics, Inc. Reports Material Event - Stock Titan
RTRX6388605 Bond Coupon Analysis — Rate & Payments - TradingView
Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes - MSN
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - Yahoo Finance
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - The Motley Fool
MSN Money - MSN
Travere Therapeutics analysts increase their forecasts following Q1 earnings - MSN
RTRX6388605 Bond Price and Chart — FINRA:RTRX6388605 - TradingView
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Travere (TVTX) Q4 2025 Earnings Transcript - AOL.com
Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing - Moomoo
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics Prices Upsized $475 Million Debt Offering - Moomoo
Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing - Moomoo
Travere Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-05-07 - Seeking Alpha
[424B5] Travere Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case - Sahm
Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing - Moomoo
Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing - marketscreener.com
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):